BioHarvest Sciences (BHST) secures $1.4M Israel AI R&D funding
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
BioHarvest Sciences Inc. reported that the Israel Innovation Authority approved a 4.33 million NIS (approximately USD $1.4 million) grant, structured as a non-dilutive, zero-interest loan. Repayment is contingent on predefined commercial milestones and is expected to come solely from revenues generated by the funded project, with no equity or equity-linked securities issued.
The funding supports a new research initiative that integrates advanced data science, machine learning, computer vision and high-throughput digital sensing into BioHarvest’s plant cell culture workflows, aiming to shift from trial-and-error to predictive, data-driven optimization and higher active metabolite yields. This is the second Israel Innovation Authority grant to BioHarvest this year, with the first focused on automating the manufacturing facility and the new grant targeting the early-stage R&D pipeline through predictive AI, together spanning discovery through to large-scale production.
Positive
- None.
Negative
- None.
Key Figures
IIA grant amount: 4.33 million NIS
Approximate USD value: USD $1.4 million
Number of IIA grants in 2026: 2
+2 more
5 metrics
IIA grant amount
4.33 million NIS
Approved non-dilutive grant from Israel Innovation Authority to fund a new research initiative
Approximate USD value
USD $1.4 million
Approximate value of the 4.33 million NIS Israel Innovation Authority grant
Number of IIA grants in 2026
2
This marks the second grant BioHarvest has received from the Israel Innovation Authority this year
Date of material change
July 15, 2026
Date specified as the material change and news release date
Investor relations phone
604 622-1187
Contact number for David Ryan, Secretary and VP, Investor Relations
Key Terms
non-dilutive funding, plant cell culture, bioinformatics, chemo-informatics, +2 more
6 terms
non-dilutive funding financial
"This non-dilutive funding will support a new research initiative"
Non-dilutive funding is money a company raises that does not require issuing new shares or reducing existing owners’ percentage ownership, such as grants, certain loans, contract revenue, or licensing deals. It matters to investors because it lets a company finance growth or research without shrinking shareholder stakes or changing control, much like topping up a car’s gas tank instead of selling part of the car to pay for the trip.
plant cell culture technical
"accelerating its plant cell culture programs"
A plant cell culture is a laboratory method that grows plant cells, tissues, or tiny plant fragments in controlled liquid or gel trays instead of in soil, like keeping a miniature garden under glass. Investors care because it lets companies produce plant-based compounds—such as flavors, pigments, medicines or active ingredients—more reliably and at scale, reducing reliance on crops, lowering supply-chain risk, and creating opportunities for recurring revenue and intellectual property.
bioinformatics technical
"by combining bioinformatics, chemo-informatics and artificial intelligence"
The use of computer tools and data analysis to organize and interpret large biological datasets, such as DNA, protein or patient information. It matters to investors because it speeds up research, lowers development costs and helps identify promising drug targets, diagnostics or personalized treatments—think of it as using GPS and analytics to find the fastest, most reliable route through vast amounts of lab data.
chemo-informatics technical
"by combining bioinformatics, chemo-informatics and artificial intelligence"
A field that uses computers, databases and statistical methods to organize, analyze and model chemical and molecular information. It turns complex chemical data into searchable patterns, predictions and visual maps—like using GPS and analytics to navigate a vast landscape of possible molecules. It matters to investors because it can speed drug discovery, reduce lab costs and highlight promising compounds earlier, affecting development timelines, budgets and potential returns.
high-throughput digital sensing technical
"computer vision and high-throughput digital sensing directly into BioHarvest’s workflows"
commercial milestones financial
"Repayment is contingent upon the achievement of certain predefined commercial milestones"
FAQ
What material change did BioHarvest Sciences (BHST) report on July 15, 2026?
BioHarvest Sciences (BHST) reported approval of a 4.33 million NIS (about USD $1.4 million) grant from the Israel Innovation Authority, structured as a non-dilutive, zero-interest loan to support a new predictive AI-driven plant cell culture research initiative.
How large is the Israel Innovation Authority grant to BioHarvest Sciences (BHST)?
The Israel Innovation Authority approved a 4.33 million NIS grant for BioHarvest Sciences (BHST), described as approximately USD $1.4 million. The funding will back advanced data science and AI integration into the company’s plant cell culture research and development workflows.
What will BioHarvest Sciences (BHST) use the new IIA grant for?
BioHarvest will use the new funding to build a predictive, data-driven plant cell culture platform, integrating bioinformatics, chemo-informatics, machine learning, computer vision and high-throughput digital sensing to forecast propagation success and maximize active metabolite and bioactive yields.
How does this second IIA grant differ from the first grant to BioHarvest (BHST) in 2026?
The first 2026 IIA grant focused on scaling the manufacturing facility with industrial automation and machine learning. The second grant targets early-stage R&D, using predictive AI to transform laboratory discovery, together linking intelligent discovery with autonomous commercial production.
What are the repayment terms of the Israel Innovation Authority grant to BioHarvest (BHST)?
The grant is structured as a non-dilutive, zero-interest loan. Repayment is contingent on achieving predefined commercial milestones and is expected to be made solely from future revenues generated by the specific project funded by the Israel Innovation Authority.